{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:27:09Z","timestamp":1786980429189,"version":"build-2736575974"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2016,11,21]],"date-time":"2016-11-21T00:00:00Z","timestamp":1479686400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Kyowa Hakko Kirin Co., Ltd."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Bone Miner Metab"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1007\/s00774-016-0797-0","type":"journal-article","created":{"date-parts":[[2016,11,21]],"date-time":"2016-11-21T01:40:17Z","timestamp":1479692417000},"page":"616-622","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Cinacalcet hydrochloride relieves hypercalcemia in Japanese patients with parathyroid cancer and intractable primary hyperparathyroidism"],"prefix":"10.1007","volume":"35","author":[{"given":"Yasuhiro","family":"Takeuchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daishu","family":"Miura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Katagiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriaki","family":"Nakashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroko","family":"Ohishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryutaro","family":"Shimazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Tominaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,11,21]]},"reference":[{"key":"797_CR1","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/S0002-9610(97)00228-6","volume":"175","author":"AC Cordeiro","year":"1998","unstructured":"Cordeiro AC, Montenegro FL, Kulcsar MA, Dellanegra LA, Tavares MR, Michaluart P Jr, Ferraz AR (1998) Parathyroid carcinoma. Am J Surg 175:52\u201355","journal-title":"Am J Surg"},{"key":"797_CR2","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/00001622-200001000-00007","volume":"12","author":"DL Fraker","year":"2000","unstructured":"Fraker DL (2000) Update on the management of parathyroid tumors. Curr Opin Oncol 12:41\u201348","journal-title":"Curr Opin Oncol"},{"key":"797_CR3","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1210\/jcem.86.2.7207","volume":"86","author":"E Shane","year":"2001","unstructured":"Shane E (2001) Parathyroid carcinoma. J Clin Endocrinol Metab 86:485\u2013493","journal-title":"J Clin Endocrinol Metab"},{"key":"797_CR4","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/B978-012098651-4\/50031-6","volume-title":"The parathyroids","author":"JL Stock","year":"2001","unstructured":"Stock JL, Marcus R (2001) Medical management of primary hyperparathyroidism in the United States. In: Bilezikian JP (ed) The parathyroids. Academic, San Diego, pp 459\u2013474"},{"key":"797_CR5","doi-asserted-by":"crossref","first-page":"4040","DOI":"10.1073\/pnas.95.7.4040","volume":"95","author":"EF Nemeth","year":"1998","unstructured":"Nemeth EF, Steffey ME, Hammerland LG, Hung BCP, Van Wagenen BC, Delmar EG, Balandrin MF (1998) Calcimimetics with potent and selective activity on the parathyroid calcium receptor. Proc Natl Acad Sci U S A 95:4040\u20134045","journal-title":"Proc Natl Acad Sci U S A"},{"key":"797_CR6","doi-asserted-by":"crossref","first-page":"3803","DOI":"10.1210\/jc.2007-0585","volume":"92","author":"SJ Silverberg","year":"2007","unstructured":"Silverberg SJ, Rubin MR, Faiman C, Peacock M, Shoback DM et al (2007) Cinacalcet hydrochloride reduces the serum calcium concentration in inoperable parathyroid carcinoma. J Clin Endocrinol Metab 92:3803\u20133808","journal-title":"J Clin Endocrinol Metab"},{"key":"797_CR7","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1210\/jc.2004-0842","volume":"90","author":"M Peacock","year":"2005","unstructured":"Peacock M, Bilezikian JP, Klassen PS, Guo MD, Turner SA et al (2005) Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism. J Clin Endocrinol Metab 90:135\u2013141","journal-title":"J Clin Endocrinol Metab"},{"key":"797_CR8","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1210\/jcem.83.4.4726","volume":"83","author":"MT Collins","year":"1998","unstructured":"Collins MT, Skarulis MC, Bilezikian JP, Silverberg SJ, Spiegel AM, Marx SJ (1998) Treatment of hypercalcemia secondary to parathyroid carcinoma with a novel calcimimetic agent. J Clin Endocrinol Metab 83:1083\u20131088","journal-title":"J Clin Endocrinol Metab"},{"key":"797_CR9","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1001\/archinte.1975.00330120072010","volume":"135","author":"WY Au","year":"1975","unstructured":"Au WY (1975) Calcitonin treatment of hypercalcemia due to parathyroid carcinoma: synergistic effect of prednisone on long-term treatment of hypercalcemia. Arch Intern Med 135:1594\u20131597","journal-title":"Arch Intern Med"},{"key":"797_CR10","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1136\/pgmj.70.821.231","volume":"70","author":"PG Newrick","year":"1994","unstructured":"Newrick PG, Braatvedt GD, Webb AJ, Sheffield E, Corrall RJM (1994) Prolonged remission of hypercalcaemia due to parathyroid carcinoma with pamidronate. Postgrad Med J 70:231\u2013232","journal-title":"Postgrad Med J"},{"key":"797_CR11","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0140-6736(85)91989-0","volume":"1","author":"K Mann","year":"1985","unstructured":"Mann K (1985) Oral biphosphonate therapy in metastatic parathyroid carcinoma. Lancet 1:101\u2013102","journal-title":"Lancet"},{"key":"797_CR12","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/S0140-6736(84)91143-7","volume":"2","author":"D Jungst","year":"1984","unstructured":"Jungst D (1984) Disodium clodronate effective in management of severe hypercalcaemia caused by parathyroid carcinoma. Lancet 2:1043","journal-title":"Lancet"},{"key":"797_CR13","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1681\/ASN.2005070679","volume":"7","author":"R Levi","year":"2006","unstructured":"Levi R, Ben-Dov IZ, Lavi-Moshayoff V, Dinur M, Martin D, Naveh-Many T, Silver J (2006) Increased parathyroid hormone gene expression in secondary hyperparathyroidism of experimental uremia is reversed by calcimimetics: correlation with posttranslational modification of the trans acting factor AUF1. J Am Soc Nephrol 7:107\u2013112","journal-title":"J Am Soc Nephrol"},{"key":"797_CR14","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1124\/jpet.103.057273","volume":"308","author":"EF Nemeth","year":"2004","unstructured":"Nemeth EF, Heaton WH, Miller M, Fox J, Balandrin MF, Van Wagenen BC, Colloton M, Karbon W, Scherrer J, Shatzen E, Rishton G, Scully S, Qi M, Harris R, Lacey D, Martin D (2004) Pharmacodynamics of the type II calcimimetic compound cinacalcet HCl. J Pharmacol Exp Ther 308:627\u2013635","journal-title":"J Pharmacol Exp Ther"},{"key":"797_CR15","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1210\/jc.2008-2640","volume":"94","author":"C Marcocci","year":"2009","unstructured":"Marcocci C, Chanson P, Shoback D, Bilezikian J, Fernandez-Cruz L, Orgiazzi J, Henzen C, Cheng S, Sterling LR, Lu J, Peacock M (2009) Cinacalcet reduces serum calcium concentrations in patients with intractable primary hyperparathyroidism. J Clin Endocrinol Metab 94:2766\u20132772","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Journal of Bone and Mineral Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00774-016-0797-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-016-0797-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-016-0797-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,15]],"date-time":"2019-09-15T16:07:28Z","timestamp":1568563648000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00774-016-0797-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,21]]},"references-count":15,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["797"],"URL":"https:\/\/doi.org\/10.1007\/s00774-016-0797-0","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.727010330.793540727","asserted-by":"object"}]},"ISSN":["0914-8779","1435-5604"],"issn-type":[{"value":"0914-8779","type":"print"},{"value":"1435-5604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,21]]}}}